ABTHealthcare · Medical DevicesThe 28 Wall Street analysts covering Abbott Laboratories hold a median 12-month price target of $120 — +16.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Abbott Laboratories on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Issuance (37): The company has been issuing shares or taking on financing, diluting existing holders.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ABT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.5% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Overweight | $120 |
| 2 Oct 2026 | Rothschild & Co | Upgrade | Buy | $119 → $127 |
| 8 Sept 2026 | TD Cowen | Reiterates | Buy | — |
| 8 Sept 2026 | TD Cowen | Reiterates | Buy | $135 |
| 25 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 21 Aug 2026 | TD Cowen | Maintains | Buy | $115 → $135 |
| 21 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 14 Aug 2026 | Citigroup | Maintains | Buy | — |
| 13 Aug 2026 | Wolfe Research | Upgrade | Outperform | — |
| 13 Aug 2026 | Wolfe Research | Upgrade | Outperform | $130 |
| 28 July 2026 | UBS | Maintains | Buy | $135 → $125 |
| 28 July 2026 | UBS | Maintains | Buy | — |
| 17 July 2026 | BTIG | Maintains | Buy | — |
| 17 July 2026 | BTIG | Maintains | Buy | $131 → $134 |
| 17 July 2026 | Citigroup | Maintains | Buy | $108 → $112 |
| 17 July 2026 | Citigroup | Maintains | Buy | — |
| 17 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 17 July 2026 | Evercore ISI Group | Maintains | Outperform | $112 → $120 |
| 17 July 2026 | JP Morgan | Maintains | Overweight | $110 → $120 |
| 17 July 2026 | JP Morgan | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Abbott Laboratories returned −21.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 23% of US stocks
Cheaper than 31% of US stocks
Cheaper than 27% of US stocks
Cheaper than 18% of US stocks
Higher than 59% of US stocks
Higher than 11% of US stocks
Higher than 69% of US stocks
Higher than 72% of US stocks
Higher than 73% of US stocks
Higher than 65% of US stocks
Higher than 78% of US stocks
Higher than 82% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Abbott Laboratories has a market value of $178.7B and an enterprise value of $204.0B.
Revenue in the twelve months to 31 Mar 2026: $45.1B. The latest quarter grew 13.0% year on year.
Net income over the same four quarters: $6.3B, a 13.9% net margin.
Diluted earnings per share, trailing twelve months: $3.57.
Free cash flow in the twelve months to 31 Mar 2026: $7.4B, after $2.1B of capital spending.
Abbott Laboratories spent $793.0M on share buybacks and $4.2B on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: 33.1×; forward P/E: 16.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.45%, paying out 79% of earnings.
Abbott Laboratories employs 122,000 people — $370K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Abbott Laboratories — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The fund review says Abbott slightly missed earnings estimates in the first part of the year before the fund invested, while digesting its Exact Sciences acquisition and facing turmoil in medtech and infant nutrition.
Why it matters — The review highlights recent earnings and operating pressures cited for Abbott, though it does not provide further detail on the company's current performance.
The article compares Medtronic and Abbott as Dividend Kings, noting that Medtronic pays more today while Abbott has raised its dividend faster. It describes their differing approaches to rewarding income investors.
Why it matters — ABT watchers may find the comparison relevant when assessing Abbott’s dividend growth relative to Medtronic’s current payout.
Longleaf Partners Fund said the market is regaining confidence in Avantor’s organic growth and turnaround plan. It also reported solid results from Regeneron, while Fortune Brands Innovations’ Q3 share price decline reversed its prior-quarter gain.
Why it matters — The excerpt discusses other companies rather than Abbott Laboratories, so it provides no specific update on ABT.
The article says the Shiller CAPE ratio has reached a level not seen since the dot-com era and describes the author adding defensive ballast by investing in three Dividend Kings from SCHD.
Why it matters — The article discusses a defensive investing approach, which may be relevant to ABT watchers, but the excerpt does not mention Abbott Laboratories.
A Zacks Investment Research item says Abbott’s Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum, and Nutrition innovations. It also notes that the stock’s valuation is below historical levels.
Why it matters — ABT watchers may be interested in the cited business drivers and valuation context ahead of the Q3 earnings report.
The 28 Wall Street analysts covering Abbott Laboratories have a median 12-month price target of $120, with estimates ranging from $103 to $135. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Abbott Laboratories, 24 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abbott Laboratories 58 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Abbott Laboratories ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +16.5% from the last close, and Ticker Nerd's factor model ranks Abbott Laboratories 58 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Abbott Laboratories publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $135 over the next 12 months.
Abbott Laboratories returned -21.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical products and solutions. Abbott Laboratories operates across four core segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.
The most recent item we track (Seeking Alpha, 14 Oct 2026): "Longleaf Partners Global Fund Q3 2026 Portfolio Review". The fund review says Abbott slightly missed earnings estimates in the first part of the year before the fund invested, while digesting its Exact Sciences acquisition and facing turmoil in medtech and infant nutrition.
Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical products and solutions. Abbott Laboratories operates across four core segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices. Its portfolio includes branded generic medicines, laboratory and point-of-care diagnostic systems, infant, pediatric and adult nutrition products, and devices used in cardiovascular care, diabetes management, and neuromodulation. The company serves hospitals, laboratories, healthcare providers, retailers, and consumers worldwide, making it an important participant in both everyday care and specialized medical treatment. Abbott Laboratories is widely recognized for combining diagnostics, nutrition, and device-based therapies within a single diversified healthcare platform.
CEO Mr. Robert B. Ford · 122,000 employees · United States · https://www.abbott.com
